WallStSmart

Sandisk Corp (SNDK)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 34% more annual revenue ($12.00B vs $8.93B). VRTX leads profitability with a 32.9% profit margin vs -11.7%. VRTX earns a higher WallStSmart Score of 66/100 (B-).

SNDK

Hold

49

out of 100

Grade: D+

Growth: 7.3Profit: 5.0Value: 5.0Quality: 8.0
Piotroski: 4/9Altman Z: 1.82

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for SNDK.

VRTXUndervalued (+36.6%)

Margin of Safety

+36.6%

Fair Value

$716.04

Current Price

$454.00

$262.04 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SNDK5 strengths · Avg: 9.8/10
Operating MarginProfitability
35.5%10/10

Strong operational efficiency at 35.5%

Revenue GrowthGrowth
61.2%10/10

Revenue surging 61.2% year-over-year

EPS GrowthGrowth
618.0%10/10

Earnings expanding 618.0% YoY

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Market CapQuality
$104.75B9/10

Large-cap with strong market position

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$115.32B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

SNDK4 concerns · Avg: 2.8/10
Price/BookValuation
10.3x4/10

Trading at 10.3x book value

Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
-9.4%2/10

ROE of -9.4% — below average capital efficiency

Profit MarginProfitability
-11.7%1/10

Currently unprofitable

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.224/10

Expensive relative to growth rate

P/E RatioValuation
29.7x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : SNDK

The strongest argument for SNDK centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 61.2% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : SNDK

The primary concerns for SNDK are Price/Book, Altman Z-Score, Return on Equity.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

SNDK profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

SNDK is growing revenue faster at 61.2% — sustainability is the question.

SNDK generates stronger free cash flow (980M), providing more financial flexibility.

Monitor COMPUTER HARDWARE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VRTX scores higher overall (66/100 vs 49/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sandisk Corp

TECHNOLOGY · COMPUTER HARDWARE · USA

Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?